📣 VC round data is live. Check it out!

Zhejiang Ausun Valuation Multiples

Discover Zhejiang Ausun's revenue and EBITDA valuation multiples and investment history, alongside public comparables like Phibro Animal Health, HBM Holdings, Guilin Sanjin, Avalyn Pharma and more.

Zhejiang Ausun Overview

About Zhejiang Ausun

Zhejiang Ausun Pharmaceutical Co Ltd is mainly engaged in the research and development, production and sales of specialty APIs and pharmaceutical intermediates, as well as providing customized production and research for customers. Its products portfolio includes Prostaglandins and their intermediates, Raw material medicine, Fluorine series and Develop products.


Founded

2010

HQ

China

Employees

N/A

Financials (FY)

Revenue: $117M
EBITDA: $33M

EV

$1B

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Zhejiang Ausun Financials

Zhejiang Ausun reported last fiscal year revenue of $117M and EBITDA of $33M.

In the same fiscal year, Zhejiang Ausun generated $63M in gross profit, $33M in EBITDA, and $19M in net income.

Revenue (LTM)


Zhejiang Ausun P&L

In the most recent fiscal year, Zhejiang Ausun reported revenue of $117M and EBITDA of $33M.

Zhejiang Ausun is profitable as of last fiscal year, with gross margin of 54%, EBITDA margin of 28%, and net margin of 16%.

See analyst estimates for Zhejiang Ausun
Last FY202320242025202620272028
Revenue$117M$121M$118M$117M
Gross Profit$63M$66M$64M$63M
Gross Margin54%55%54%54%
EBITDA$33M$50M$46M$33M
EBITDA Margin28%42%39%28%
EBIT Margin17%32%26%17%
Net Profit$19M$38M$31M$19M
Net Margin16%31%26%16%

Financial data powered by Morningstar, Inc.

Zhejiang Ausun Stock Performance

Zhejiang Ausun has current market cap of $1B, and enterprise value of $1B.

Market Cap Evolution


Zhejiang Ausun's stock price is $1.40.

Zhejiang Ausun share price decreased by 0.1% in the last 30 days, and increased by 10.7% in the last year.

Zhejiang Ausun has an EPS (earnings per share) of $0.02.

See more trading valuation data for Zhejiang Ausun
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$1B$1B-2.1%-0.1%-5.6%10.7%$0.02

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Zhejiang Ausun Valuation Multiples

Zhejiang Ausun trades at 9.1x EV/Revenue multiple, and 32.7x EV/EBITDA.

See NTM and 2027E valuation multiples for Zhejiang Ausun

EV / Revenue (LTM)


Zhejiang Ausun Financial Valuation Multiples

As of June 4, 2026, Zhejiang Ausun has market cap of $1B and EV of $1B.

Zhejiang Ausun has a P/E ratio of 60.3x.

Last FY202320242025202620272028
EV/Revenue9.1x8.8x9.1x9.1x
EV/EBITDA32.7x21.2x23.1x32.7x
EV/EBIT52.0x27.5x35.0x52.0x
EV/Gross Profit17.0x16.0x16.7x17.0x
P/E60.3x31.0x38.1x60.3x
EV/FCF138.4x123.4x108.1x138.4x

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Zhejiang Ausun Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Zhejiang Ausun Margins & Growth Rates

In the most recent fiscal year, Zhejiang Ausun reported gross margin of 54%, EBITDA margin of 28%, and net margin of 16%.

See estimated margins and future growth rates for Zhejiang Ausun

Zhejiang Ausun Margins

Last FY20242025202720282029
Gross Margin54%54%54%
EBITDA Margin28%39%28%
EBIT Margin17%26%17%
Net Margin16%26%16%
FCF Margin7%8%7%

Zhejiang Ausun Growth Rates

23/2424/2526/2727/2828/29
Revenue Growth(3%)(0%)
Gross Profit Growth(4%)(2%)
EBITDA Growth(8%)(29%)
EBIT Growth(21%)(33%)
Net Profit Growth(19%)(37%)
FCF Growth14%(22%)

Data powered by FactSet, Inc. and Morningstar, Inc.

Zhejiang Ausun Operational KPIs

Access forward-looking KPIs for Zhejiang Ausun
Last FY202320242025202620272028
S&M Expenses to Revenue1%1%1%1%
G&A Expenses to Revenue6%6%6%6%
R&D Expenses to Revenue21%10%13%21%
Opex to Revenue36%23%28%36%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Zhejiang Ausun Competitors

Zhejiang Ausun competitors include Phibro Animal Health, HBM Holdings, Guilin Sanjin, Avalyn Pharma, MedinCell, Youcare Pharmaceutical, Marksans Pharma, TOWA Pharmaceutical, Bio-Thera Solutions and Aktis Oncology.

Most Zhejiang Ausun public comparables operate across Biopharmaceuticals, BioTech and DeepTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Phibro Animal Health1.4x1.3x10.2x7.6x
HBM Holdings5.2x4.4x8.4x8.1x
Guilin Sanjin3.3x-10.2x-
Avalyn Pharma--(11.1x)(10.4x)
MedinCell39.9x29.6x(91.1x)(412.4x)
Youcare Pharmaceutical2.9x-(968.9x)-
Marksans Pharma3.5x3.4x15.0x16.6x
TOWA Pharmaceutical1.4x1.3x7.6x7.9x

This data is available for Pro users. Sign up to see all Zhejiang Ausun competitors and their valuation data.

Start Free Trial

Investments by Zhejiang Ausun

Zhejiang Ausun has invested in 1 company to date.

Latest investment by Zhejiang Ausun was on December 1st 2020. Zhejiang Ausun invested in IMPACT Therapeutics in their $50M Series C round (EV/Revenue multiple available to Pro users).

See VC round multiples

Latest Investments by Zhejiang Ausun

IMPACT Therapeutics
Description
IMPACT Therapeutics is a Pudong-headquartered biopharmaceutical company developing first-in-class targeted cancer therapies based on synthetic lethality. Focused on DNA damage response pathways, it advances clinical-stage assets including tusamitamab ravtansine and josonalide for solid tumors. The firm collaborates with partners like Bayer and Eli Lilly, with operations in China and Europe since its 2010 founding.
HQ CountryChina
HQ City
Nanjing
Deal Date1 Dec 2020
RoundSeries C
Raised$50M
InvestorsAJ Asset Management; China Summit Capital; Lilly Asia Ventures; Shanghai Junshi; West Fountain Global Fund; Zhejiang Ausun; Zhenji Capital
Valuationundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Zhejiang Ausun investments and their VC round multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Zhejiang Ausun

When was Zhejiang Ausun founded?Zhejiang Ausun was founded in 2010.
Where is Zhejiang Ausun headquartered?Zhejiang Ausun is headquartered in China.
Is Zhejiang Ausun publicly listed?Yes, Zhejiang Ausun is a public company listed on Shanghai Stock Exchange.
What is the stock symbol of Zhejiang Ausun?Zhejiang Ausun trades under 603229 ticker.
When did Zhejiang Ausun go public?Zhejiang Ausun went public in 2017.
Who are competitors of Zhejiang Ausun?Zhejiang Ausun main competitors include Phibro Animal Health, HBM Holdings, Guilin Sanjin, Avalyn Pharma, MedinCell, Youcare Pharmaceutical, Marksans Pharma, TOWA Pharmaceutical, Bio-Thera Solutions, Aktis Oncology.
What is the current market cap of Zhejiang Ausun?Zhejiang Ausun's current market cap is $1B.
What is the current revenue of Zhejiang Ausun?Zhejiang Ausun's last fiscal year revenue is $117M.
What is the current EV/Revenue multiple of Zhejiang Ausun?Current revenue multiple of Zhejiang Ausun is 9.1x.
Is Zhejiang Ausun profitable?No, Zhejiang Ausun is not profitable.
How many companies Zhejiang Ausun has acquired to date?Zhejiang Ausun hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies Zhejiang Ausun has invested to date?As of June 2026, Zhejiang Ausun has invested in 1 company.
What was the last Zhejiang Ausun investment?On 1st December 2020 Zhejiang Ausun invested in IMPACT Therapeutics, participating in a $50M Series C round, alongside AJ Asset Management, China Summit Capital, Lilly Asia Ventures, Shanghai Junshi, West Fountain Global Fund, and Zhenji Capital.
In what companies Zhejiang Ausun invested in?Zhejiang Ausun invested in IMPACT Therapeutics.

See public comps similar to Zhejiang Ausun

Lists including Zhejiang Ausun

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial